Experienced in Autoimmune Hepatitis

Dr. Doo-sang Cho

Gastroenterology
6020 E Arbor Ave, #101, 
Mesa, AZ 
Experienced in Autoimmune Hepatitis
6020 E Arbor Ave, #101, 
Mesa, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Doo-sang Cho is a Gastroenterologist in Mesa, Arizona. Dr. Cho is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hepatitis. His top areas of expertise are Esophagitis, Familial Adenomatous Polyposis, Gastroesophageal Reflux Disease (GERD), and Barrett Esophagus.

His clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gastroenterology
Licenses
Internal Medicine in AZ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

6020 E Arbor Ave, #101, Mesa, AZ 85206

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Enrollment Status: Terminated
Publish Date: May 11, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials
Similar Doctors
Advanced in Autoimmune Hepatitis
Dr. Keith D. Lindor
Hepatology | Gastroenterology
Advanced in Autoimmune Hepatitis
Dr. Keith D. Lindor
Hepatology | Gastroenterology
13400 E Shea Blvd, 
Scottsdale, AZ 
 (12.9 miles away)
480-301-8000
Languages Spoken:
English

Keith Lindor is a Hepatologist and a Gastroenterologist in Scottsdale, Arizona. Dr. Lindor is rated as an Elite provider by MediFind in the treatment of Autoimmune Hepatitis. His top areas of expertise are Cholangitis, Sclerosing Cholangitis, Primary Biliary Cholangitis, Liver Transplant, and Endoscopy.

Advanced in Autoimmune Hepatitis
Dr. Mark Griffin
Gastroenterology
Advanced in Autoimmune Hepatitis
Dr. Mark Griffin
Gastroenterology

Bhsm Rehabilitation LLC

5605 W Eugie Ave, Suite 212and215, 
Glendale, AZ 
 (30.7 miles away)
602-865-5830
Languages Spoken:
English
See accepted insurances

Mark Griffin is a Gastroenterologist in Glendale, Arizona. Dr. Griffin is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hepatitis. His top areas of expertise are Familial Adenomatous Polyposis, Gardner Syndrome, Turcot Syndrome, Endoscopy, and Colonoscopy.

Advanced in Autoimmune Hepatitis
Dr. Ronald Hauptman
Gastroenterology
Advanced in Autoimmune Hepatitis
Dr. Ronald Hauptman
Gastroenterology

Arizona Digestive Health PC

9250 N 3rd St, Suite 4035, 
Phoenix, AZ 
 (23.8 miles away)
602-279-3575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ronald Hauptman is a Gastroenterologist in Phoenix, Arizona. Dr. Hauptman is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hepatitis. His top areas of expertise are Hiatal Hernia, Congenital Diaphragmatic Hernia, Gastroesophageal Reflux Disease (GERD), Gastrectomy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cho's expertise for a condition
ConditionClose
      View All 24 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile